Research programme: antibody therapeutics - Minotaur Therapeutics
Latest Information Update: 26 Apr 2024
At a glance
- Originator Minotaur Therapeutics
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Immunological disorders
Most Recent Events
- 18 Apr 2024 Early research in Cancer in USA (Parenteral) prior to April 2024 (Minotaur Therapeutics pipeline, April 2024)
- 18 Apr 2024 Early research in Immunological disorders in USA (Parenteral) prior to April 2024 (Minotaur Therapeutics pipeline, April 2024)